Omalizumab: all 165 studies that test it
Page 1 of 2. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyNot yet recruitingNCT07845552Phase 4
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingNCT07816328Phase 3
- A Study to Find a Suitable Dose of Exl-111 for Further ResearchRecruitingNCT07356713Phase 1
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDRecruitingNCT07059091Phase 2
- Omalizumab Weight-Based Dosing Efficacy TrialRecruitingNCT06943534Phase 2
- Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE LevelsRecruitingNCT06934200Phase 2
- Effect of Omalizumab in the Skin of Food Allergy PatientsRecruitingNCT06618963Phase 4
- Biologics and Sublingual ImmunotherapyNot yet recruitingNCT06027073Phase 4
- Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous UrticariaRecruitingNCT05916937Phase 4
- Omalizumab Before Onset of ExacerbationsRecruitingNCT05332067Phase 2
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsCompletedNCT04998604Phase 4Results posted
- Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedNCT04976192Phase 3Results posted
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaCompletedNCT04426890Phase 3Results posted
- A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic AsthmaTerminatedNCT04195958Phase 4Results posted
- To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy SubjectsCompletedNCT04018313Phase 1Results posted
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic ParticipantsCompletedNCT03881696Phase 3Results posted
- Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)CompletedNCT03679676Phase 2Results posted
- An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedNCT03478930Phase 3Results posted
- Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsCompletedNCT03369704Phase 3Results posted
- Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous UrticariaCompletedNCT03328897Phase 3Results posted
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedNCT03280550Phase 3Results posted
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal PolypsCompletedNCT03280537Phase 3Results posted
- Multi OIT to Test Immune Markers After Minimum Maintenance DoseCompletedNCT03181009Phase 2Results posted
- Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)CompletedNCT03111628Phase 4Results posted
- Treatment of Idiopathic Angioedema With Xolair as Add-on TherapyCompletedNCT02966314Phase 4Results posted
- Sputum-derived Cellular Targets After Xolair (Omalizumab)TerminatedNCT02658877Phase 4Results posted
- Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsCompletedNCT02654145Phase 4Results posted
- Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic PatientsCompletedNCT02643862Phase 1/2Results posted
- Multi Immunotherapy to Test Tolerance and XolairCompletedNCT02626611Phase 2Results posted
- Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE TreatmentCompletedNCT02550106Phase 4Results posted
- A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic UrticariaCompletedNCT02392624Phase 4Results posted
- Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With RhinovirusCompletedNCT02388997Phase 2Results posted
- Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria PatientsCompletedNCT02329223Phase 3Results posted
- Omalizumab in Severe and Refractory Solar UrticariaCompletedNCT02262130Phase 2Results posted
- Urticaria Facticia Treatment With Omalizumab (UFO)CompletedNCT02169115Phase 2Results posted
- OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) PatientsCompletedNCT02161562Phase 3Results posted
- Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in BasophilsCompletedNCT02023151Phase 4Results posted
- A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)CompletedNCT01922037Phase 4Results posted
- Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated AsthmaTerminatedNCT01912872Phase 4Results posted
- Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical TrialCompletedNCT01781637Phase 1/2Results posted
- Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to TherapyCompletedNCT01723072Phase 3Results posted
- Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic UrticariaCompletedNCT01701583Phase 4Results posted
- Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine TreatmentCompletedNCT01599637Phase 2Results posted
- Cold Urticaria Treatment With XolairCompletedNCT01580592Phase 2Results posted
- Preventative Omalizumab or Step-up Therapy for Severe Fall ExacerbationsCompletedNCT01430403Phase 4Results posted
- A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)CompletedNCT01292473Phase 3Results posted
- Xolair Enhances Oral Desensitization in Peanut Allergic PatientsCompletedNCT01290913Phase 1/2Results posted
- A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT01287117Phase 3Results posted
- A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor AntagonistsCompletedNCT01264939Phase 3Results posted
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 TherapyCompletedNCT01202903Phase 3Results posted
- OIT and Xolair® (Omalizumab) in Cow's Milk AllergyCompletedNCT01157117Phase 2Results posted
- A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyCompletedNCT01125748Phase 4Results posted
- Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal PolyposisCompletedNCT01066104Phase 2Results posted
- Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled AsthmaCompletedNCT01007149Phase 3Results posted
- The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen ChallengeCompletedNCT01003301Phase 2Results posted
- Omalizumab in the Treatment of Peanut AllergyCompletedNCT00949078Phase 2Results posted
- Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut AllergyCompletedNCT00932282Phase 1/2Results posted
- A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic AnaphylaxisCompletedNCT00890162Phase 2Results posted
- Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic AsthmaCompletedNCT00870584Phase 4Results posted
- A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)CompletedNCT00866788Phase 2Results posted
- Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic AsthmaCompletedNCT00829179Phase 3Results posted
- An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)TerminatedNCT00787917Phase 4Results posted
- A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE LevelsCompletedNCT00624832Phase 4Results posted
- The Effect of Omalizumab on Responses to Cat Allergen ChallengeCompletedNCT00604786Not applicableResults posted
- Therapeutic Utility of Xolair in Patients Undergoing Aspirin DesensitizationCompletedNCT00555971Phase 4Results posted
- Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.CompletedNCT00500539Phase 3Results posted
- A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced AsthmaCompletedNCT00495612Phase 4Results posted
- Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic UrticariaCompletedNCT00481676Phase 2Results posted
- Efficacy and Safety of Omalizumab in Bullous PemphigoidCompletedNCT00472030Phase 4Results posted
- Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic AsthmaCompletedNCT00454051Phase 4Results posted
- A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic AsthmaCompletedNCT00434434Phase 2Results posted
- Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic RhinoconjunctivitisCompletedNCT00396409Phase 3Results posted
- A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788gCompletedNCT00382148Phase 2Results posted
- Inner-City Anti-IgE Therapy for AsthmaCompletedNCT00377572Phase 4Results posted
- Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)CompletedNCT00367016Phase 4Results posted
- A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)CompletedNCT00314574Phase 3Results posted
- A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE TherapyCompletedNCT00283504Phase 4Results posted
- Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaCompletedNCT00267202Phase 4Results posted
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic AsthmaCompletedNCT00264849Phase 4Results posted
- Immune Dysfunction in Allergic AsthmaCompletedNCT00189228Not applicableResults posted
- Effect of Anti-IgE in Non-Allergic AsthmaTerminatedNCT00162773Phase 2Results posted
- A Pilot Study of the Treatment of Eosinophilic Esophagitis With OmalizumabCompletedNCT00123630Phase 2Results posted
- A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)CompletedNCT00096954Phase 4Results posted
- Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic AsthmaCompletedNCT00079937Phase 3Results posted
- ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene ExpressionCompletedNCT06869382Phase 4
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative StudyCompletedNCT06806826Phase 4
- FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FAActive, not recruitingNCT06437171Phase 4
- E-B-FAHF-2, Multi OIT and Xolair for Food AllergyCompletedNCT06103656Phase 2
- Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic AsthmaCompletedNCT05813470Phase 3
- Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedNCT05774639Phase 3
- PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult SubjectsCompletedNCT05564611Phase 1
- Omalizumab Efficacy in Patients With Refractory Nasal PolypsStatus unknownNCT05405478Phase 4
- A Prospective Study on Optimizing Treatment for ABPAStatus unknownNCT05129033Not applicable
- Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous UrticariaStatus unknownNCT04944602Phase 3
- Gastrointestinal STRING Test With Oral ImmunotherapyTerminatedNCT04943744Early Phase 1
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and SafetyCompletedNCT04778137Phase 1
- Molecular Endotypes of Chronic Idiopathic UrticariaActive, not recruitingNCT04774315Phase 4
- COVID-19 Immunologic Antiviral Therapy With OmalizumabStatus unknownNCT04720612Phase 2
- Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair®CompletedNCT04601389Phase 1
- Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".Status unknownNCT04585997Phase 4